Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) had its target price dropped by investment analysts at RBC Capital Markets from $187.00 to $177.00 in a research note issued to investors on Friday. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. RBC Capital Markets’ price objective suggests a potential upside of 37.40% from the stock’s current price.

A number of other equities research analysts have also recently weighed in on the company. Royal Bank Of Canada reduced their price objective on Alexion Pharmaceuticals from $187.00 to $177.00 and set an “outperform” rating for the company in a research note on Friday. Credit Suisse Group restated a “buy” rating and set a $160.00 price target on shares of Alexion Pharmaceuticals in a research note on Friday. Cowen and Company restated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Thursday. Oppenheimer Holdings, Inc. assumed coverage on Alexion Pharmaceuticals in a research note on Wednesday, February 8th. They set a “hold” rating for the company. Finally, J P Morgan Chase & Co set a $170.00 price target on Alexion Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, February 7th. Seven investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Alexion Pharmaceuticals currently has an average rating of “Buy” and an average price target of $169.20.

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 1.20% during midday trading on Friday, reaching $128.82. 3,048,171 shares of the company were exchanged. The company has a 50 day moving average of $131.34 and a 200-day moving average of $127.08. The company has a market capitalization of $28.93 billion, a price-to-earnings ratio of 73.19 and a beta of 1.39. Alexion Pharmaceuticals has a 52-week low of $109.12 and a 52-week high of $162.00.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, February 16th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.25 by $0.01. Alexion Pharmaceuticals had a return on equity of 10.58% and a net margin of 12.46%. The company earned $831 million during the quarter, compared to analysts’ expectations of $840.69 million. During the same quarter in the previous year, the business earned $1.13 earnings per share. The firm’s revenue for the quarter was up 18.5% on a year-over-year basis. On average, equities research analysts anticipate that Alexion Pharmaceuticals will post $5.27 earnings per share for the current fiscal year.

“Alexion Pharmaceuticals, Inc. (ALXN) Price Target Cut to $177.00” was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this piece can be read at http://www.dailypolitical.com/2017/02/17/alexion-pharmaceuticals-inc-alxn-pt-lowered-to-177-00-at-rbc-capital-markets.html.

In other Alexion Pharmaceuticals news, Director Alvin S. Parven sold 22,659 shares of the company’s stock in a transaction on Thursday, January 5th. The stock was sold at an average price of $138.35, for a total value of $3,134,872.65. Following the sale, the director now owns 14,305 shares of the company’s stock, valued at $1,979,096.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Leonard Bell sold 246 shares of the company’s stock in a transaction on Thursday, February 9th. The shares were sold at an average price of $126.84, for a total value of $31,202.64. Following the completion of the sale, the director now directly owns 394,648 shares in the company, valued at approximately $50,057,152.32. The disclosure for this sale can be found here. Insiders sold 80,784 shares of company stock worth $10,961,334 in the last three months. 4.41% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the stock. Municipal Employees Retirement System of Michigan raised its stake in Alexion Pharmaceuticals by 0.3% in the third quarter. Municipal Employees Retirement System of Michigan now owns 7,090 shares of the biopharmaceutical company’s stock valued at $869,000 after buying an additional 20 shares during the period. Bremer Trust National Association raised its stake in Alexion Pharmaceuticals by 0.5% in the third quarter. Bremer Trust National Association now owns 5,478 shares of the biopharmaceutical company’s stock valued at $672,000 after buying an additional 26 shares during the period. Wedbush Securities Inc. raised its stake in Alexion Pharmaceuticals by 0.6% in the third quarter. Wedbush Securities Inc. now owns 4,915 shares of the biopharmaceutical company’s stock valued at $602,000 after buying an additional 29 shares during the period. MSI Financial Services Inc raised its stake in Alexion Pharmaceuticals by 1.0% in the third quarter. MSI Financial Services Inc now owns 4,290 shares of the biopharmaceutical company’s stock valued at $526,000 after buying an additional 44 shares during the period. Finally, Mn Services Vermogensbeheer B.V. raised its stake in Alexion Pharmaceuticals by 0.8% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 5,735 shares of the biopharmaceutical company’s stock valued at $703,000 after buying an additional 44 shares during the period. 94.98% of the stock is currently owned by institutional investors.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.